Evaluation of the effect of curcumin-piperine supplement in patients with acute ischemic stroke

Evaluation of the effect of curcumin-piperine supplement administration on the severity of injury and function in patients with acute ischemic stroke

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201220049774N4

Enrollment

Registered

2022-11-18

Start date

2022-12-07

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke. Cerebral infarction due to cerebral venous thrombosis, nonpyogenic

Interventions

Intervention 1: Intervention group: 34 patients in the curcumin-piperine supplement group, as soon as possible after confirming the diagnosis of acute ischemic stroke, will receive curcumin-piperine t

Eligibility

Sex/Gender

All

Age

50 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age between 18 and 80 years Less than 24 hours have passed since the onset of stroke. The patient has been diagnosed with an acute ischemic stroke. GCS of the patient at the time of visit should be more than 13. The NIHSS range is between 5 and 20. MRS is less than 2 before the onset of stroke. Sign the informed consent form

Exclusion criteria

Exclusion criteria: Patients receiving rtPA Candidate patients for endovascular treatment, mechanical thrombectomy or craniotomy Pregnancy or breastfeeding History of allergy to turmeric or black pepper Taking immunosuppressive drugs Concomitant receipt of any drug or supplement with an antioxidant or anti-inflammatory effect or an approved immune system regulator

Design outcomes

Primary

Measure	Time frame
Assessment of stroke severity based on NIH Stroke Scale (NIHSS). Timepoint: Days 0 and 4 of study. Method of measurement: Questionnaire.;Evaluation of patients' performance based on Modified Rankin Scale (MRS) and Barthel index (BI). Timepoint: Days 0, 4 and 30 of the study. Method of measurement: Questionnaire.	—

Secondary

Measure	Time frame
Complete blood count with differential. Timepoint: Once at study entry and again after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;Total and direct bilirubin. Timepoint: Once at study entry and again after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;C-reactive protein (CRP). Timepoint: Once at study entry and again after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;Hemoglobin A1c (HbA1c). Timepoint: Once at study entry and again after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;Early death. Timepoint: One week and one month after starting the study. Method of measurement: Information about the patient's condition by phone call.	—

Measure

Time frame

Complete blood count with differential. Timepoint: Once at study entry and again after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;Total and direct bilirubin. Timepoint: Once at study entry and again after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;C-reactive protein (CRP). Timepoint: Once at study entry and again after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;Hemoglobin A1c (HbA1c). Timepoint: Once at study entry and again after receiving the last dose of curcumin-piperine. Method of measurement: Laboratory tests.;Early death. Timepoint: One week and one month after starting the study. Method of measurement: Information about the patient's condition by phone call.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHesamoddin Hosseinjani

Mashhad University of Medical Sciences

hosseinjanih@mums.ac.ir+98 51 3180 1586

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026